300267 Stock Overview
Manufactures and sells APIs, finished drug products, and pharmaceutical excipients in China and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Hunan Er-Kang Pharmaceutical Co., Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥2.47 |
| 52 Week High | CN¥3.93 |
| 52 Week Low | CN¥2.08 |
| Beta | 0.39 |
| 1 Month Change | 2.92% |
| 3 Month Change | -6.08% |
| 1 Year Change | -24.23% |
| 3 Year Change | -39.46% |
| 5 Year Change | -50.50% |
| Change since IPO | -82.81% |
Recent News & Updates
Recent updates
Shareholder Returns
| 300267 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -5.4% | -3.1% | -0.6% |
| 1Y | -24.2% | -12.1% | -10.5% |
Return vs Industry: 300267 underperformed the CN Pharmaceuticals industry which returned -11.4% over the past year.
Return vs Market: 300267 underperformed the CN Market which returned -9.1% over the past year.
Price Volatility
| 300267 volatility | |
|---|---|
| 300267 Average Weekly Movement | 7.0% |
| Pharmaceuticals Industry Average Movement | 5.8% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in CN Market | 10.5% |
| 10% least volatile stocks in CN Market | 4.2% |
Stable Share Price: 300267 has not had significant price volatility in the past 3 months.
Volatility Over Time: 300267's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 1,497 | Qingrong Sun | www.hnerkang.com |
Hunan Er-Kang Pharmaceutical Co., Ltd manufactures and sells APIs, finished drug products, and pharmaceutical excipients in China and internationally. Its APIs include glycerin, dilute hydrochloric acid, sulbenicillin sodium, dihydroxypropyl theophylline, calamine powder, sulfadiazine, sulphaguanidine, TMP, and resorcinol. The company’s finished drugs primarily comprise sulbenicillin sodium for injection and compound liquorice tablets.
Hunan Er-Kang Pharmaceutical Co., Ltd Fundamentals Summary
| 300267 fundamental statistics | |
|---|---|
| Market cap | CN¥5.09b |
| Earnings (TTM) | -CN¥218.50m |
| Revenue (TTM) | CN¥1.51b |
3.4x
P/S Ratio-23.3x
P/E RatioIs 300267 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300267 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.51b |
| Cost of Revenue | CN¥1.27b |
| Gross Profit | CN¥240.20m |
| Other Expenses | CN¥458.70m |
| Earnings | -CN¥218.50m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.11 |
| Gross Margin | 15.89% |
| Net Profit Margin | -14.45% |
| Debt/Equity Ratio | 7.4% |
How did 300267 perform over the long term?
See historical performance and comparison